https://www.selleckchem.com/pr....oducts/sndx-5613.htm
quality, and comparability of future economic evaluations in osteoporosis. This updated review provides an overview of recently published cost-effectiveness analyses. In comparison with a previous review, recent economic evaluations of anti-osteoporosis drugs were conducted in more countries and included more active drugs and sequential therapy as interventions/comparators. The updated economic evidence could help decision makers prioritize health interventions and the unmet/unreported quality issues indicated by the osteoporosis-spec
Respect!
Kommentar
Delen
